Repligen Corporation

Repligen Corporation

RGEN

$186.75

Updated: 23/09/2026, 13:44:41

Market Cap
$10.54B
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Stock valuation chart
One-year closing share-price history for RGEN
Company Profile

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

USD
NASDAQ
CEO: Olivier Loeillot
Employees: 2,000
https://www.repligen.com
Asset Summaries
Latest generated summaries for RGEN

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for RGEN.
Share price
$186.75
Market cap
$10.54B
Exchange
NASDAQ
Currency
USD
CEO
Olivier Loeillot
Employees
2,000
IPO date
29/04/1986
Beta
1.048
Last dividend
$0.00
Day range
$180.00 – $188.19
52-week range
$100.99 – $188.73
1-day performance
3.34%
1-year performance
84.92%
Current drawdown (1Y)
-1.05%
CIK
0000730272
CUSIP
759916109
ISIN
US7599161095
Created
07/12/2025, 13:58:52
Last update
23/09/2026, 13:44:41

Track Repligen Corporation with an AI analyst

See which prediction-market events move RGEN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to RGEN from your Railway `news_articles` table.

Repligen Corp (RGEN) Shares Surge 3.8% -- What GF Score of 83 Tells Investors

GuruFocus • STOCK • 09/06/2026, 21:58:00

Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Seeking Alpha • STOCK • 03/06/2026, 20:21:59

Repligen Has A Cleaner Recovery Angle, But With High Valuation

Seeking Alpha • STOCK • 31/05/2026, 11:15:00

Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference

GlobeNewsWire • STOCK • 22/05/2026, 09:30:00

Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report

GlobeNewsWire • STOCK • 20/05/2026, 09:30:00

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 12/05/2026, 18:11:29

Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises

Zacks Investment Research • STOCK • 06/05/2026, 14:50:41

Repligen (NASDAQ: RGEN) Delivers Strong Q1 2026 Results and Positive Analyst Outlook

Market Data • Market Data • 05/05/2026, 23:21:18

Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 05/05/2026, 16:41:19

Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates

Zacks Investment Research • STOCK • 05/05/2026, 12:15:58

Repligen to Report First Quarter 2026 Financial Results

GlobeNewsWire • STOCK • 22/04/2026, 09:30:00

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

GlobeNewsWire • STOCK • 17/04/2026, 09:30:00